Analytic Investors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 59.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,003,604 shares of the biopharmaceutical company’s stock after buying an additional 374,709 shares during the period. Analytic Investors LLC owned about 0.08% of Gilead Sciences worth $79,405,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Philadelphia Trust Co. raised its position in Gilead Sciences by 4.4% in the third quarter. Philadelphia Trust Co. now owns 15,831 shares of the biopharmaceutical company’s stock worth $1,253,000 after buying an additional 670 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in Gilead Sciences by 30.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 676,204 shares of the biopharmaceutical company’s stock worth $53,501,000 after buying an additional 157,850 shares in the last quarter. Davidson Investment Advisors raised its position in Gilead Sciences by 39.9% in the third quarter. Davidson Investment Advisors now owns 197,221 shares of the biopharmaceutical company’s stock worth $15,601,000 after buying an additional 56,290 shares in the last quarter. Carnegie Capital Asset Management LLC raised its position in Gilead Sciences by 11.3% in the third quarter. Carnegie Capital Asset Management LLC now owns 40,527 shares of the biopharmaceutical company’s stock worth $2,944,000 after buying an additional 4,126 shares in the last quarter. Finally, HBK Investments L P raised its position in Gilead Sciences by 93.2% in the third quarter. HBK Investments L P now owns 226,177 shares of the biopharmaceutical company’s stock worth $17,895,000 after buying an additional 109,131 shares in the last quarter. Institutional investors and hedge funds own 74.62% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up 1.17% during trading on Friday, hitting $66.36. The stock had a trading volume of 16,208,423 shares. Gilead Sciences, Inc. has a 12-month low of $65.38 and a 12-month high of $103.10. The stock’s 50-day moving average is $72.26 and its 200-day moving average is $75.71. The stock has a market capitalization of $87.33 billion, a P/E ratio of 6.68 and a beta of 1.11.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.61 by $0.09. The business had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $7.16 billion. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. Gilead Sciences’s quarterly revenue was down 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.32 earnings per share. Analysts predict that Gilead Sciences, Inc. will post $8.88 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Thursday, March 16th will be given a $0.52 dividend. The ex-dividend date is Tuesday, March 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.13%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.47. Gilead Sciences’s payout ratio is currently 18.91%.
A number of research firms recently issued reports on GILD. Barclays PLC restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday. Leerink Swann set a $74.00 price target on Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday. JPMorgan Chase & Co. set a $82.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday. BMO Capital Markets reiterated a “hold” rating and set a $75.00 price target (down previously from $88.00) on shares of Gilead Sciences in a research report on Thursday. Finally, RBC Capital Markets reduced their price target on Gilead Sciences to $75.00 in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $88.94.
In related news, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now owns 121,761 shares in the company, valued at $9,115,028.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total value of $5,396,869.83. Following the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at approximately $235,814,224.47. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/analytic-investors-llc-has-79405000-position-in-gilead-sciences-inc-gild/1655289.html
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.